Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible! Dex 40mg weekly in #MMsm induction: 1️⃣ Not practical even for trial-enrolled patients 2️⃣ Does not improve PFS vs ⬇️ dex Twitter 🧵 once I’m back from #IMS24! https://t.co/1Sy1WQpHjk

After a college student finally found a treatment that worked for his ulcerative colitis, UnitedHealthcare decided it wouldn’t pay for the costly drugs. His fight to get coverage exposed the insurer’s hidden procedures for rejecting claims. https://t.co/xgdFU4alHd

Rick Pazdur set to leave FDA after only a few weeks in his new position as top drug officer. Decades of tireless civil service to this country at the Agency. Best of luck in his next chapter. https://t.co/cgrir2AujB

#ASH25 is DAYS away—time to get organized! Download the official meeting app to: ✅ Build your personalized schedule ✅ Access 8,200+ abstract full texts ✅ Use the NEW AI assistant to navigate ✅ Get convention center maps & updates 🔗 Pro tip: Log in with your ASH

I’m taking over ⁦@TargetedOnc⁩ for #ASH25. #mmsm Tune in ☺️

I am hopeful that both parties can go back to the table to negotiate for ALL Canadians MM patients with @MyelomaCanada

We know from @Areejmd & colleagues that sexual dysfunction & anxiety after #HSCT are common, and this is just one subset of patients & partners affected. Docs often either don’t talk about it or give very cautious advice. Suggestions from @sigruneinarsdo1 for where to start:

During all of my training, we have told patients who are severely neutropenic to avoid sexual activity. That recommendation comes from an abundance of caution but relatively little evidence. Is it time to rethink those assumptions? Now in @JCOOP_ASCO: https://t.co/mUovFo227P

Ready, set… hunt! 👀 Join the first-ever #ASHScavengerHunt at #ASH25! Explore, snap, and share your experience at the 2025 ASH Annual Meeting and Exposition. Register now: https://t.co/9hOe8b23Jz

11) LBA3: MajesTEC-3 (B): Tec-Dara vs Dara-Pd/Dara-Vd 📰Patients with 1-3 prior lines and without prior anti-CD38 refractoriness or BCMA exposure were randomized to Tec-Dara vs DPd/DVd. Tec went to q2weeks for cycles 3-6, and q4weeks thereafter. 📊Clear and substantial PFS

10) LBA1: KLN-1010 (Ho et al.) – in-vivo CAR T is coming fast and furious. Here we have (very) preliminary but encouraging results from 3 patients treated with an LD-chemo-free in-vivo-CAR T KLN-1010. The premise is to modify endogenous T-cells to become BCMA-directed CAR T

7) Abstract 697 (@Myeloma_Doc) – Ph1 LINKER-MM4. Linvo monotherapy +/- transplant. Transplant eligible patients received limited duration linvo; ineligible patients received linvo until progression. 📊ORR 79% but 86% at the 50-200 mg doses. 52% MRD negativity by ITT. No

6) Abstract 269 (Richard et al.) – DURGA-1 study with AZD0120 – same product in RRMM. ⏲️Median time from apheresis to release 14 days and vein-to-vein 28 days. 👍Only 1.4 months follow-up but among 15 evaluable patients, ORR 100% and all MRD evaluable patients were MRD<10^-5.

5) Abstract 258 (Du et al.): GC012F/AZD0120 in newly diagnosed myeloma following 2 cycles of VRd. This dual-targeting BCMA/CD19 FasTCAR led to a 30-month PFS of 88% and 82% sustained MRD negativity, which ranks among the best of outcomes in newly diagnosed MM! 🤔Clearly we are

4) Abstract 256 (@DrKrinaPatel): iMMagine-1 – Anito-cel BCMA CAR T in triple-class exposed RRMM. PFS rate at 18-months 66% which compares mostly favorably with others. No IEC-enterocolitis or atypical neurologic toxicities seen thus far. Most important thing at this point is

3) Abstract 248 (@dikokaz): Could consolidation with a bispecific antibody supplant transplant? IMMUNOPLANT is a ph2 study enrolling patients with MRD positivity after 4+ cycles of induction. 💉Patients received 4-6 cycles of linvoseltamab before maintenance 👍MRD conversion to

2) Abstract 99 (Dytfeld): Disclosure I am an author. The phase 3 COBRA trial compared weekly KRd x 24 cycles vs. VRdx8/Rdx16. Longer course of KRd makes complicates direct comparison but...VRd is hard to administer for long periods of time due to neuropathy (whereas K can be

My top 11 myeloma/amyloidosis abstracts I’m excited about, spanning bispecifics, CAR T, MRD and amyloid clearance. Stay tuned for a much longer discussion at the end re: MajesTEC-3... 1) Abstract 94 (@End_myeloma): CARTITUDE-4 Long-term PFS with cilta-cel in standard-risk

@RahulBanerjeeMD @BloodPortfolio @fredhutch @mshadman @UWDeptMedicine @Rcl14L Such an interesting phenomenon in those excellent responders!

Thank you Kate this is a great list. Grateful to all the haem experts guiding us @VincentRK @Papa_Heme @RahulBanerjeeMD @ManniMD1 @Rfonsi1 @graham74GC @MAWildgust Exciting times and real progress for our patients

@mtmdphd @grpetersen1 @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @bdermanmd @szusmani @DrOlaLandgren @VincentRK @myelomaMD @bhemato @MeeraMohanMD @HealthTree @IMFmyeloma @Larvol @NorthTxMSG @IMFjimMYELOMA @MyelomaTeacher now that LBA are out, please add my "vote" to the 2 MM LBA 🙏🏼